Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress
- 26 June 2023
- journal article
- editorial
- Published by Wiley in American Journal of Hematology
- Vol. 98 (9) , 1350-1353
Abstract
No abstract availableFunding Information
- Novartis
- British Mycological Society
- Takeda
- Ascentage Pharma
This publication has 19 references indexed in Scilit:
- Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated PhaseClinical Lymphoma Myeloma and Leukemia, 2014
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up resultsLeukemia, 2011
- Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A TrialJournal of Clinical Oncology, 2009
- Staging of chronic myeloid leukemia in the imatinib eraCancer, 2006
- Survival benefit with imatinib mesylate therapy in patients with accelerated‐phase chronic myelogenous leukemia—Comparison with historic experienceCancer, 2005
- The World Health Organization (WHO) classification of the myeloid neoplasmsBlood, 2002
- Characteristics of accelerated disease in chronic myelogenous leukemiaCancer, 1988
- Unfavorable Signs in Patients with Chronic Myelocytic LeukemiaAnnals of Internal Medicine, 1972
- Characteristics of the Terminal Phase of Chronic Granulocytic LeukemiaBlood, 1968